Clinical Trial
MagSense® HER2 Breast Cancer Phase I Study – IBI010103
Imagion Biosystems is currently conducting an investigational Phase 1 study of a novel imaging agent. This first-in-human study is investigating the safety of the agent and the feasibility to detect metastatic disease in the axillary nodes in subjects with HER2-positive (HER2+) primary breast cancer when used with Magnetic Resonance Imaging (MRI) and Magnetic Relaxometry (MRX). The Phase I study is a first-of-its-kind clinical study using molecularly targeted magnetic nanoparticle technology to detect tumor cells in vivo in the lymph nodes of human breast cancer patients.
The imaging agent is specifically designed for breast cancer patients that test positive for the Human Epidermal Growth Factor Receptor 2 (HER2).
This study aims to show that this new targeted imaging agent is safe and has the potential to non-invasively find out if breast cancer has spread to the lymph nodes.
Details of the study can be found at Australia New Zealand Clinical Trial Registry.
If you are interested in learning more, please contact Imagion Biosystems
MagSense® Technology will transform cancer diagnosis
- Non-invasive – a safe and non-surgical solution to detect cancer
- No radioactivity – uses bio-safe magnetic nanoparticles to “tag” cancer cells
- Specific – use of targeted imaging agent provides molecular confirmation of the presence of cancer not just a suspicion
- Platform technology – can be used for many cancers as well as other diseases